To develop and validate a multiparametric prognostic model, incorporating dynamic contrast-enhanced (DCE) quantitative parameters and multi-modality radiomic features, for the accurate identification of isocitrate dehydrogenase 1 (IDH1) mutation status from glioma patients. Here, IDH1 is linked to glioma.